MENA Newswire, NEW YORK: Novo Nordisk’s blockbuster weight-loss drug Wegovy is now available in an oral pill form in the United States, marking a major milestone in obesity treatment. The new tablet version, approved by the U.S. Food and Drug Administration in December 2025, contains the same active ingredient, semaglutide, as the injectable version that has gained widespread use among patients seeking medical support for weight management. This release makes Wegovy the first and only GLP-1 receptor agonist for chronic weight management to be offered as a once-daily pill. Wegovy, developed by the Danish pharmaceutical company Novo Nordisk, works by mimicking the GLP-1 hormone that regulates appetite and food intake. It is designed for adults who are obese or overweight and have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.
The oral version is available by prescription and is intended to be used in combination with a reduced-calorie diet and increased physical activity. Novo Nordisk said the pill is now available in retail pharmacies and through telehealth providers across the country. The company introduced the tablet form to offer patients a needle-free alternative to weekly injections. The new dosage regimen requires the pill to be taken once daily on an empty stomach, at least 30 minutes before eating, drinking, or taking other medications. Patients are advised to take it with a small amount of water to ensure proper absorption. This daily routine contrasts with the injectable form of Wegovy, which is administered once a week. Clinical testing indicated that the pill demonstrated comparable weight-loss efficacy when taken as directed. In clinical trials known as the OASIS studies, patients taking oral semaglutide lost an average of 14 to 17 percent of their body weight over 64 weeks, depending on adherence and dosage.
Participants were also following a calorie-restricted diet and physical activity program. These results are consistent with the outcomes reported for the injectable formulation of Wegovy, confirming the pill’s effectiveness in long-term weight management for adults with obesity. Pricing for the oral Wegovy will vary depending on dosage and insurance coverage. Novo Nordisk said self-paying patients can expect to pay approximately 149 to 299 U.S. dollars per month, depending on the prescribed strength. Many insured patients are likely to qualify for lower out-of-pocket costs through savings programs and health insurance plans that include obesity treatments in their coverage. Analysts noted that the oral formulation’s lower production and distribution costs compared to injectable versions could expand access to treatment for a broader patient base. The company stated that pricing will remain consistent with its commitment to ensuring affordability while maintaining reliable supply.
Oral semaglutide shows strong weight loss results
As with the injectable version, common side effects of the Wegovy pill include nausea, vomiting, diarrhea, and abdominal discomfort. These effects are generally temporary and tend to lessen over time as the body adjusts to treatment. The medication carries the same boxed warning as other semaglutide products regarding the potential risk of thyroid C-cell tumors observed in rodent studies. It is contraindicated for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Healthcare professionals advise that patients discuss their full medical history before beginning therapy. The introduction of an oral Wegovy tablet expands the availability of GLP-1-based therapies, a class of medications that has rapidly reshaped the treatment of obesity and metabolic disease.
Demand for these drugs has surged in the past two years, with millions of prescriptions filled for semaglutide-based medications such as Ozempic and Wegovy. The shift from injections to a once-daily tablet is expected to simplify adherence for some patients who prefer oral dosing and may enhance overall continuity of care in obesity management. Novo Nordisk said the company continues to focus on ensuring consistent supply and broad distribution of both injectable and oral forms of Wegovy to meet high patient demand in the United States. Pharmacies nationwide began receiving shipments of the tablets in early January, with availability confirmed through major pharmacy chains and online healthcare platforms. The company also stated that it is expanding educational efforts to support physicians and pharmacists in guiding patients through the new dosing protocol.
Insurance coverage expands affordability nationwide
The release of the Wegovy pill marks a significant development in the treatment of obesity, providing patients and physicians with a new, non-injectable option backed by robust clinical evidence. The convenience of an oral formulation, coupled with comparable efficacy and established safety data, positions the medication as a major advancement in chronic weight management. As obesity continues to affect more than 40 percent of American adults, the availability of Wegovy in pill form offers a new pathway for patients seeking medically supervised, evidence-based treatment for sustainable weight loss. The introduction of this once-daily tablet may also improve adherence among patients hesitant to use injectable therapies, supporting long-term treatment continuity and better health outcomes. With proven results in clinical studies and wide pharmacy availability, Wegovy’s oral form represents a pivotal step in broadening access to obesity care nationwide.